peptides for healing

updated

the healing-peptide shelf is built on rodent data. zero compounds in this category have a phase-3 tendon or wound-repair indication.

as of may 2026 no peptide marketed for tendon, ligament, or soft-tissue healing has an fda-approved repair indication. bpc-157 has 200+ rodent papers from the sikiric zagreb lab and zero phase-3 rcts. tb-500 was isolated by goldstein in 1981 and banned by USEF in 2014. ghk-cu has the best cosmetic record in the category but the connective-tissue case is mostly extrapolation. kpv is a three-residue alpha-msh fragment with promising colitis biology in mice.

blend rows grade their named components, not a fixed product. gut-barrier, tissue-protection, immune, bone-fracture, and patient-neurology evidence does not establish generic tendon, ligament, or wound repair.

the repair cluster.

compounds most often discussed in tendon, ligament, wound, and soft-tissue contexts. evidence is strongest mechanistically and in rodent models, thinner in controlled human trials.

  • ghk-cu (tier S) · copper-binding tripeptide isolated from human plasma by Pickart in 1973. shifted expression of 31.2% of 13,424 measured genes by 50% or more in two cell lines (Pickart, BioMed Res Int 2014). · the deepest mechanistic file in the healing category. extracellular-matrix and angiogenesis biology is well documented. the cosmetic record is stronger than the deep connective-tissue record. orthopedic outcome trials do not exist.
  • bpc-157 (tier A) · 15-amino-acid gastric pentadecapeptide. 200+ rodent papers from the Sikiric lab in Zagreb. zero phase-3 rcts as of may 2026. · the center of the healing category and the largest preclinical-to-human-trial gap on the site. heavy clinical-community use, no FDA-approved indication. on april 22, 2026 the FDA removed BPC-157 from category 2 of the section 503A bulk-substances list. on july 23, 2026 the PCAC discussed it as a nominated bulk drug substance being considered for the 503A bulks list, and news reports put its vote at 8 to 6, with 1 abstention, to recommend it, a non-binding vote, not an approval.
  • tb-500 (tier A) · thymosin beta-4 fragment. parent peptide isolated by Goldstein in 1981 from thymus tissue. banned by USEF in 2014 as a horse-doping agent. · the systemic half of the repair conversation. published biology maps to actin sequestration and cell migration in rodent wound models. human outcome data is thinner than the reputation. the veterinary doping precedent is the largest in-vivo human-relevant signal.
  • bpc-157 + tb-500 blend (tier A) · two repair-pathway peptides paired for local signaling plus cell-migration biology. · the blend makes mechanistic sense because the pathways are complementary. there is no controlled trial of the combination in humans. it does not replace diagnosis, imaging, rehab, or surgical judgment.

adjacent biology, thinner outcomes.

these compounds appear in healing searches, but the evidence points to inflammation, mitochondrial disease, or bone-fracture outcomes rather than direct tendon, ligament, or wound repair.

  • klow (tier A) · kpv, bpc-157, ghk-cu, and tb-500 in one compounded blend. · four mechanisms in one commercial vial. useful as a map of what compounding clinics combine. zero blend-specific clinical outcome data. the april 22, 2026 FDA 503A action on BPC-157, TB-500, KPV, and injectable GHK-Cu put the formula in pharmacy limbo. at the july 23, 2026 PCAC review the committee then voted 8 to 6, with 1 abstention, news reports say, to recommend each of BPC-157, TB-500 and KPV for the 503A bulks list. the votes are non-binding, and GHK-Cu was not on the agenda.
  • ss-31 (tier A) · elamipretide, mitochondria-targeted tetrapeptide. FDA accelerated approval september 2025 (Forzinity) for Barth syndrome, a rare cardiolipin disorder. · not a general healing peptide. relevant where mitochondrial dysfunction is the research question. one approved indication, n<200 globally. the fda decision is real, the use case is narrow.
  • kpv (tier B) · lysine-proline-valine. c-terminal tripeptide of alpha-msh. picomolar nf-kb inhibition in dss-colitis mouse models (Kannengiesser et al, IBD 2008). · inflammation biology more than tissue-repair biology. promising mechanistic record in mouse colitis and skin models. no fda-approved indication. clinical human trials limited to small dermatology pilots.
  • tb-500 fragment (tier C) · short actin-binding fragment of thymosin beta-4. typically the LKKTETQ heptapeptide. · cheaper to synthesize than full tb-500, with a narrower evidence base (Goldstein & Kleinman, Vitam Horm 2015 for the parent biology, fragment-specific outcome trials zero). the fragment rationale is plausible. the clinical record is not built.
  • Abaloparatide (tier S) · Abaloparatide is an FDA-approved subcutaneous bone-anabolic peptide for high-risk osteoporosis. It reduced vertebral fractures in studied postmenopausal women; it is not an adult-height intervention. · Daily subcutaneous abaloparatide reduced new vertebral fractures in postmenopausal women with osteoporosis and increased BMD in men with osteoporosis. Neither trial measured adult height or reopening of growth plates.
  • larazotide (tier D) · larazotide acetate (AT-1001) is an eight-amino-acid oral tight-junction regulator. a celiac phase 2b found a symptom benefit at 0.5 mg three times daily, but the pivotal phase 3 was terminated after an interim sample-size review and posted no results. · the phase 2b symptom signal did not become pivotal confirmation: the celiac phase 3 was terminated without posted results. the molecule remains in a separate Long COVID study, also without posted results, and has no US approval.
  • ghk-cu + bpc blend (tier A) · the surface-and-structure repair pairing. ghk-cu rebuilds skin and collagen, bpc-157 works on connective tissue and gut. component evidence first, fixed-blend trial evidence absent. · two well-characterized repair peptides in one vial. GHK-Cu covers skin, collagen, and dermal remodeling; BPC-157 covers connective tissue, gut lining, and vascular repair. the grade is on each molecule's published evidence, not on any vial.
  • bpc-157 + kpv blend (tier A) · gut and systemic anti-inflammatory repair. bpc-157 carries the blend, kpv adds the NF-kB anti-inflammatory leg. strong mechanism, thinner human proof on the second component. · a gut-and-repair pairing built on the strongest component in the gray-peptide world plus a clean anti-inflammatory tripeptide. BPC-157 carries the grade; KPV adds the inflammation leg.
  • cibinetide (tier D) · eleven amino acids copied from erythropoietin, the hormone that tells the body to make more red blood cells. the copy keeps the half of that hormone which protects injured tissue and leaves the red cells alone. vendors label it ARA-290. six published human trials, five of them randomised, and two primary endpoints that separated. · does it work: mixed. it was tested mostly in people whose smallest nerves had been damaged by sarcoidosis or by diabetes, and it never beat placebo on how much pain those people were in. two main endpoints did beat placebo across the whole human record. one was the amount of nerve visible in photographs of the eye surface, at one dose out of three, corneal nerve fibre area at 4 mg (p=0.012). the other was an average blood-sugar reading in a diabetes trial, HbA1c in type 2 diabetes (p=0.002). nobody outside the group that invented it has repeated either. roughly 130 people have ever been dosed.
  • vip (tier D) · a chemical the body makes in its own gut, lungs and nerves to widen blood vessels and relax the muscle in the walls of airways and gut. drug companies made a synthetic copy of it and took it into trials for damaged lungs. four randomized trials in COVID-19 respiratory failure, a 665-patient meta-analysis, and a plasma half-time of about one minute. the biggest trial was stopped for futility. the one trial that clearly beat placebo is for erectile dysfunction, an indication nobody researches it for. · it was tested properly for damaged lungs and it failed there. given by intravenous drip for COVID-19 lung failure, the trials came back with no benefit. injected into the penis with phentolamine it produces an erection in most men, and that combination is licensed in three countries as Invicorp. a 461-patient NIH-run phase 3 halted for futility, a pooled survival odds ratio of 1.01 across the two randomized trials in the 2025 meta-analysis (611 patients), and one clearly positive randomized trial in erectile dysfunction by intracavernosal injection.
  • Cartalax (tier C) · an identity-gated Ala-Glu-Asp tripeptide with cell and animal work plus one poorly reported, 29-person saline-controlled human example in an assignee patent, but no independent peer-reviewed replication or measured pharmacokinetic curve. · the exact AED tripeptide has a real chemical identity, preclinical signals, and one sparse assignee-patent human signal, but the consequential claims remain behind weak reporting, absent independent replication, and a product-identity gate.

specific-question reference.

which peptides have the strongest tissue-repair evidence?

bpc-157 and tb-500 dominate the preclinical repair literature. bpc-157 carries 200+ rodent papers from the sikiric lab in zagreb. tb-500 has the goldstein 1981 thymus-isolation lineage and decades of actin-dynamics work. controlled human outcome data for both: zero phase-3 rcts as of may 2026. ghk-cu has a stronger cosmetic and wound-remodeling record than most compounds in the category.

is any peptide fda-approved for tendon or ligament healing?

no. zero peptides in this category have an fda-approved tendon or ligament repair indication. ss-31 (elamipretide / forzinity) is approved for barth syndrome, not soft-tissue repair. fda-approved status in another context does not transfer to orthopedic injury.

what does the literature say about bpc-157 plus tb-500?

the combination is mechanistically coherent. bpc-157 maps to local signaling, nitric-oxide release, and angiogenesis. tb-500 maps to actin dynamics and cell migration. controlled human trial of the combination: none on pubmed as of may 2026.

do healing peptides replace rehab or imaging?

no. published peptide research does not substitute for diagnosis, imaging, surgical evaluation, or progressive loading. the serious literature on tendon and ligament recovery still routes through mechanical rehabilitation and clinician oversight.

do any peptides help joints or recovery after surgery?

no peer-reviewed controlled human trial shows it. the joint data are mostly rodent: bpc-157 improved healing of a cut knee ligament in rats (Cerovecki, J Orthop Res 2010), and ghk-cu injected into rat knees after ACL reconstruction reduced laxity at 6 weeks but not 12 (Fu, J Orthop Res 2015). bpc-157's only human knee report is a retrospective chart review: 11 of 12 patients given it alone reported knee-pain improvement by phone, with no control group, validated measure or imaging (Lee, Altern Ther Health Med 2021). a 2026 systematic review found 3 uncontrolled human bpc-157 studies, 30 people in all (Poolton, Acta Orthop Belg 2026); a randomized bpc-157 trial after rotator cuff surgery was not yet recruiting in october 2026 (NCT07803250). zero compounds here have a phase-3 tendon, joint or wound-repair indication, and peptides do not replace diagnosis, imaging, rehab or surgical evaluation.

what the safety literature reports.

what safety gap matters most in healing peptides?

long-term human safety characterization. BPC-157 and TB-500 have heavy community use and preclinical research. neither has the formal chronic-use human safety package expected of approved drugs. on april 22, 2026 the FDA removed both molecules from category 2 of the section 503A bulk-substances list. on july 23, 2026 the PCAC discussed both as nominated bulk drug substances being considered for the 503A bulks list, and news reports put its vote at 8 to 6, with 1 abstention, to recommend each, a non-binding vote.

why does regulatory status matter here?

because repair claims become treatment claims fast. once a compound is framed as healing an injury, the standard shifts from supplement to drug. that is the gap between rodent data and fda label.

what is the cleanest way to read this category?

as a mechanism map. bpc-157, tb-500, ghk-cu, and kpv point at different repair and inflammatory pathways. the map is not a protocol.

claim checks

related comparisons

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.